SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-22-013365
Filing Date
2022-05-13
Accepted
2022-05-13 17:01:34
Documents
39
Period of Report
2022-03-31

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 541852
2 ex31-1.htm EX-31.1 18072
3 ex31-2.htm EX-31.2 18604
4 ex32-1.htm EX-32.1 7465
5 ex32-2.htm EX-32.2 7363
  Complete submission text file 0001493152-22-013365.txt   2872618

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE immx-20220331.xsd EX-101.SCH 18776
7 XBRL CALCULATION FILE immx-20220331_cal.xml EX-101.CAL 31399
8 XBRL DEFINITION FILE immx-20220331_def.xml EX-101.DEF 85263
9 XBRL LABEL FILE immx-20220331_lab.xml EX-101.LAB 233970
10 XBRL PRESENTATION FILE immx-20220331_pre.xml EX-101.PRE 166281
33 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 334292
Mailing Address 10573 W. PICO BLVD. #58 LOS ANGELES CA 90064
Business Address 11400 WEST OLYMPIC BLVD. SUITE 200 LOS ANGELES CA 90064 (888) 958-1084
Immix Biopharma, Inc. (Filer) CIK: 0001873835 (see all company filings)

IRS No.: 454869378 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41159 | Film No.: 22923766
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences